Novel splice variants derived from the receptor tyrosine kinase superfamily are potential therapeutics for rheumatoid arthritis

Table 3 Effect of alternative splice variant-expressing adenoviruses on joint inflammation and destruction

Alternative splice variant adenovirus	Mice per group (n)	Joints assessed (n)	P value
			Clinical score	Paw swelling	Histological evaluation
Untreated	6	120	-	-	-
LacZ	6	164	0.4549	0.3759	0.3797
VEGFR1-541	5	53	<0.0001	<0.0001	0.0096
VEGFR2-712	5	44	<0.0001	0.1762	0.7340
VEGFR3-765	5	68	0.9366	0.2228	0.8148
Tie1-751	6	63	<0.0001	<0.0001	<0.001
Met-877	6	64	0.2924	0.6603	0.5038
c-Kit-413	6	55	0.0587	0.1501	0.1046
CSF1R-306	6	50	0.2448	0.5581	0.1510
PDGFRβ-336	6	41	0.8498	0.0632	0.8258
FGFR1-320	6	55	0.0044	0.0087	0.0568
RAGE-387	6	53	0.8543	0.1141	0.9799

Following onset of arthritis, mice were treated with the alternative splice variant adenovirus indicated. Data presented as P values of mice treated with the indicated recombinant alternative splice variant adenoviruses as compared with untreated mice, and are expressed as the P value of clinical scores, paw swelling, and histological evaluation. For clinical scores and paw swelling, data were analyzed using two-way analysis of variance versus untreated mice. For histological evaluation, H & E and toluidine blue stained sections were scored for pannus formation, synovitis, and bone and cartilage erosion. Data were analyzed using the chi-square test for trend versus untreated mice.

ISSN: 1478-6362